Background No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap.
Methods Electronic databases were searched for randomised controlled trials (RCTs) involving diabetes patients receiving gemigliptin in the intervention arm and placebo/active comparator in the control arm. The primary outcome was change in haemoglobin A1c (HbA1c). The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events.
Results Data from 10 RCTs involving 1,792 patients were analysed. Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin as controls. HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], –0.06 to 0.23; P=0.24; I2=0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, –0.91%; 95% CI, –1.18 to –0.63); P<0.01; I2=89%; high certainty of evidence [HCE]). Gemigliptin was superior to PCG regarding achieving HbA1c <7% (12 weeks: odds ratio [OR], 5.91; 95% CI, 1.34 to 26.08; P=0.02; I2=74%; 24 weeks: OR, 4.48; 95% CI, 2.09 to 9.60; P<0.01; I2=69%; HCE). Gemigliptin was comparable to ACG regarding achieving HbA1c <7% after 24 weeks (OR, 0.92; 95% CI, 0.52 to 1.63; P=0.77; I2=66%; MCE). Adverse events were similar between the gemigliptin and control groups (risk ratio [RR], 1.06; 95% CI, 0.82 to 1.36; P=0.66; I2=35%; HCE). The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95% CI, 0.62 to 2.28; P=0.61; I2=19%; HCE).
Conclusion Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use.
Citations
Citations to this article as recorded by
Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis Lakshmi Nagendra, Deep Dutta, Sunetra Mondal, Nitin Kapoor, Ameya Joshi, Saptarshi Bhattacharya Journal of Clinical Densitometry.2024; 27(1): 101453. CrossRef
Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis Kunal Mahajan, Lakshmi Nagendra, Anil Dhall, Deep Dutta European Journal of Internal Medicine.2024;[Epub] CrossRef
Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials Yuqian Wu, Kai Wang, Jingyang Su, Xin Liu Medicine.2024; 103(8): e36916. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis Deep Dutta, Lakshmi Nagendra, Ameya Joshi, Suryashri Krishnasamy, Meha Sharma, Naresh Parajuli Obesity Surgery.2024; 34(5): 1653. CrossRef
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis Deep Dutta, Lakshmi Nagendra, Beatrice Anne, Manoj Kumar, Meha Sharma, A. B. M. Kamrul‐Hasan Obesity Science & Practice.2024;[Epub] CrossRef
Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis Lakshmi Nagendra, Deep Dutta, Harish Bukkasagar Girijashankar, Deepak Khandelwal, Tejal Lathia, Meha Sharma Annals of Pediatric Endocrinology & Metabolism.2024; 29(2): 82. CrossRef
Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis Deep Dutta, Deepak Khandelwal, Manoj Kumar, Meha Sharma Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102695. CrossRef
Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697. CrossRef
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study Soo Lim, Minji Sohn, Jose C. Florez, Michael A. Nauck, Jiyoung Ahn Nutrients.2023; 15(1): 248. CrossRef
Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy Journal of Endocrinological Investigation.2023; 46(5): 855. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Verapamil improves One-Year C-Peptide Levels in Recent Onset Type-1 Diabetes: A Meta-Analysis Deep Dutta, Lakshmi Nagendra, Nishant Raizada, Saptarshi Bhattacharya, Meha Sharma Indian Journal of Endocrinology and Metabolism.2023; 27(3): 192. CrossRef
Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis Deep Dutta, B.G. Harish, Beatrice Anne, Lakshmi Nagendra Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(8): 102816. CrossRef
Semaglutide and cancer: A systematic review and meta-analysis Lakshmi Nagendra, Harish BG, Meha Sharma, Deep Dutta Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(9): 102834. CrossRef
Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis Deep Dutta, Jyoti Kadian, Indira Maisnam, Ashok Kumar, Saptarshi Bhattacharya, Meha Sharma Indian Journal of Endocrinology and Metabolism.2023; 27(4): 286. CrossRef
Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis Lakshmi Nagendra, Kunal Mahajan, Gunjan Gupta, Deep Dutta Indian Heart Journal.2023; 75(6): 416. CrossRef
Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials Deep Dutta, Lakshmi Nagendra, Sowrabha Bhat, Ritin Mohindra, Vineet Surana, Anoop Misra Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102877. CrossRef
Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis Lakshmi Nagendra, Deep Dutta, Meha Sharma, Harish Bg touchREVIEWS in Endocrinology.2023; 19(2): 8. CrossRef
Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis Deep Dutta, Subhankar Chatterjee, Priyankar K. Datta, Ritin Mohindra, Meha Sharma Indian Journal of Endocrinology and Metabolism.2023; 27(5): 377. CrossRef
Efficacy and Safety of Ultra-rapid Lispro Insulin in Managing Type-1 and Type-2 Diabetes: A Systematic Review and Meta-Analysis Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Meha Sharma Indian Journal of Endocrinology and Metabolism.2023; 27(6): 467. CrossRef
Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis Deep Dutta, Ritin Mohindra, Vineet Surana, Meha Sharma Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(4): 102469. CrossRef
Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis D Dutta, R Jindal, D Mehta, M Kumar, M Sharma Journal of Postgraduate Medicine.2022; 68(2): 85. CrossRef
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung Biochemical and Biophysical Research Communications.2022; 626: 135. CrossRef
Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping Zouxi Du, Tingting Lu, Mingdong Gao, Limin Tian Acta Diabetologica.2022; 59(12): 1539. CrossRef
Ranirestat improves electrophysiologic but not clinical measures of diabetic polyneuropathy: A meta-analysis Deep Dutta, Ritin Mohindra, Manoj Kumar, Ashok Kumar, Meha Sharma Indian Journal of Endocrinology and Metabolism.2022; 26(5): 399. CrossRef
Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis Deep Dutta, Vineet Surana, Rajiv Singla, Sameer Aggarwal, Meha Sharma Indian Journal of Endocrinology and Metabolism.2021; 25(6): 475. CrossRef